{"disease":{"id":"multiple-sclerosis-relapse","name":"multiple sclerosis relapse"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05218317","title":"Evaluation of Relapse Presence in Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Marmara University","has_results":false},{"nct_id":"NCT05359653","title":"Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04902690","title":"The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":21,"lead_sponsor_name":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}